Tenpoint Therapeutics

Tenpoint Therapeutics: Ophthalmic treatments that rejuvenate vision in aging eyes. BioTech · Series C · Warren, United States. Rated 73/100 on Startup24.

Ophthalmic treatments that rejuvenate vision in aging eyes.

Preliminary profile · public data only

Startup24 listed Tenpoint Therapeutics from public information on the company's own website; its founders have not claimed or verified the profile yet. The rating below is preliminary, based on public data only, and is an opinion — not investment advice. Founders can claim the profile, and anyone can report an error or request removal, on this page.

At a glance

Startup24 rating: 73/100

Tenpoint Therapeutics is a later-stage ophthalmic biotech with a meaningful FDA application milestone for BRIMOCHOL PF, a specialized leadership team, and exposure to large age-related eye-care markets.

About the rating

Every startup on Startup24 is scored on the same six criteria — team, market, product, advantages, risk and reputation — with the reasoning written out. Founders list for free; investors subscribe to see the full analysis.

Startup24 (startup-24.com) rates startups on real, verified data: founders list for free, investors subscribe to find them first. Operated by DOTOVO OÜ, Tallinn, Estonia.